peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Hansa Medical granted patents in the United States and Europe for the medical use of IdeS

14 Mar 2012, 08:30
Regulatory information
Hansa Medical announced that both the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) have granted patents to Hansa Medical covering the medical use of the drug candidate IdeS.

The granted IdeS patents, U.S. Patent 8,133,483 and European patent EP 1,901,773 , cover the use of IdeS in a method for the treatment or prevention of diseases mediated by IgG antibodies, including transplant rejection and autoimmune diseases.

IdeS is Hansa Medical’s most important biopharmaceutical development program. The IgG specific enzyme IdeS is being developed for use as a once-only treatment prior to kidney transplantation of sensitized transplantation patients. Sensitized transplantation patients have significant serum levels of donor specific antibodies, making it especially challenging to find a suitable organ donor for these patients. IdeS neutralizes IgG antibodies and has the potential to make sensitized patients transplantable, and thereby shorten the waiting time for these patients. The program is in late preclinical development and the results from toxicology and safety studies are currently being evaluated. Clinical phase I studies are scheduled for mid 2012.

For further information, please contact:
Hansa Medical AB
Emanuel Björne, CEO
Mobile: 46 707 17 54 77

Hansa Medical is a drug and diagnostics discovery company focused on inflammatory diseases. The company develops innovative biological pharmaceuticals and diagnostic methods both independently and in partnership with large, established companies. At present, the company is primarily undertaking three development projects: IdeS, EndoSand HMD-301. New development projects and product candidates generated through cooperation with medical academic research are continuously evaluated. The main shareholders of Hansa Medical are Bo Håkansson via Farstorps Gård AB, and Bengt Ågerup via NXT2B AB. Hansa Medical is listed on NASDAQ OMX First North, and Remium Nordic AB is the company’s Certified Adviser.